

**Amendment to the Claims**

1 - 43. (canceled)

44. (currently amended) A method for identifying an agonist of SEQ ID NO:2, the method comprising the steps of:

a) contacting a test compound ~~potential agonist~~ with a cell expressing SEQ ID NO:2;  
and

b) determining whether in the presence of the test compound ~~potential agonist~~ the signaling activity of SEQ ID NO:2 is increased relative to the activity of SEQ ID NO:2 in the absence of the test compound ~~potential agonist~~

wherein the increased signaling activity identifies the test compound as an agonist.

45. (currently amended) A method for identifying an inverse agonist of SEQ ID NO:2, the method comprising the steps of:

a) contacting a test compound ~~potential inverse agonist~~ with a cell expressing SEQ ID NO:2; and

b) determining whether in the presence of the test compound ~~potential inverse agonist~~ the activity of SEQ ID NO:2 is decreased relative to the activity of SEQ ID NO:2 in the absence of the test compound ~~potential inverse agonist~~, and is ~~decreased in the presence of an endogenous ligand or agonist~~

wherein the decreased signaling activity identifies the test compound as an inverse agonist.

46. (currently amended) A method for identifying an antagonist of SEQ ID NO:2, the method comprising the steps of

a) contacting a test compound ~~potential antagonist~~ with a cell expressing SEQ ID NO:2; and

b) determining whether in the presence of the test compound and an endogenous ligand or agonist ~~potential antagonist~~ the signaling activity of SEQ ID NO:2 is decreased relative to the activity of SEQ ID NO:2 in the presence of an endogenous ligand or agonist

wherein the decreased signaling activity identifies the test compound as an antagonist.